Press Releases
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine. Building on the existing agreement with Europe’s Inclusive Vaccines Alliance spearheaded by Germany, France, Italy and the...
Drug Research
Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization (CDMO) focused...
Clinical Trials
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, announced that the first participant has been dosed in its...
Press Releases
FUJIFILM Diosynth Biotechnologies expands its partnership with Novavax to manufacture COVID-19 Vaccine Candidate at its Billingham site
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announce that its site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Billingham plans to...
Press Releases
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder
Roche announced that the US FDA has approved ENSPRYNGâ„¢ (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, lifelong and debilitating autoimmune disorder...
Drug Research
Memo Therapeutics and Northway Biotech collaborate on the fast-track manufacturing of a SARS-CoV-2-neutralizing antibody for the therapy of COVID-19
Swiss biotech company Memo Therapeutics AG (MTx), and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4 month fast-track process approved by...
Press Releases
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide
TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced that it has entered into a worldwide exclusive licensing agreement with UNION therapeutics...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read